Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
about
Obesity and cancerHistological evaluation of AMPK signalling in primary breast cancerFatty acid synthase inhibitors induce apoptosis in non-tumorigenic melan-a cells associated with inhibition of mitochondrial respiration.Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker.The nonsteroidal anti-inflammatory drug tolfenamic acid inhibits BT474 and SKBR3 breast cancer cell and tumor growth by repressing erbB2 expression.Fatty acid synthase inhibition by amentoflavone suppresses HER2/neu (erbB2) oncogene in SKBR3 human breast cancer cells.Inhibition of fatty acid metabolism reduces human myeloma cells proliferation.Efficacy of massage therapy on pain and dysfunction in patients with neck pain: a systematic review and meta-analysis.Metabolic alterations and targeted therapies in prostate cancer.Fatty acid synthase as a potential therapeutic target in cancer.Metformin: multi-faceted protection against cancer.Obesity and HER 2 overexpression: a common factor for poor prognosis of breast cancerPotential use of humanized antibodies in the treatment of breast cancer.Folate Receptor-Targeted Polymeric Micellar Nanocarriers for Delivery of Orlistat as a Repurposed Drug against Triple-Negative Breast CancerDevelopment of a Self-Assembled Nanoparticle Formulation of Orlistat, Nano-ORL, with Increased Cytotoxicity against Human Tumor Cell Lines.Fatty acid synthase inhibition results in a magnetic resonance-detectable drop in phosphocholine.Loss of fatty acid synthase inhibits the "HER2-PI3K/Akt axis" activity and malignant phenotype of Caco-2 cells.Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.The prince and the pauper. A tale of anticancer targeted agents.Disruption of crosstalk between the fatty acid synthesis and proteasome pathways enhances unfolded protein response signaling and cell deathFatty Acids and Breast Cancer: Make Them on Site or Have Them Delivered.Metabolic shifts induced by fatty acid synthase inhibitor orlistat in non-small cell lung carcinoma cells provide novel pharmacodynamic biomarkers for positron emission tomography and magnetic resonance spectroscopy.Inhibition of fatty acid synthase in melanoma cells activates the intrinsic pathway of apoptosis.Fatty acid synthesis is a therapeutic target in human liposarcomaComparative docking of dual conformations in human fatty acid synthase thioesterase domain reveals potential binding cavity for virtual screening of ligands.Chemical inhibition of fatty acid synthase: molecular docking analysis and biochemical validation in ocular cancer cells.Total synthesis of tetrahydrolipstatin and stereoisomers via a highly regio- and diastereoselective carbonylation of epoxyhomoallylic alcohols.The fatty acid synthase inhibitor orlistat reduces experimental metastases and angiogenesis in B16-F10 melanomas.Conjugated linoleic acid (CLA) inhibits expression of the Spot 14 (THRSP) and fatty acid synthase genes and impairs the growth of human breast cancer and liposarcoma cells.Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells.Effects of Fatty Acid Synthase Inhibition by Orlistat on Proliferation of Endometrial Cancer Cell Lines.Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells.Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA).Clinical and therapeutic relevance of the metabolic oncogene fatty acid synthase in HER2+ breast cancer.Fatty acid synthase (FASN) as a therapeutic target in breast cancer.De Novo Lipid Synthesis Facilitates Gemcitabine Resistance through Endoplasmic Reticulum Stress in Pancreatic Cancer.The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.Ratiometric Raman imaging reveals the new anti-cancer potential of lipid targeting drugsOrlistat-loaded solid SNEDDS for the enhanced solubility, dissolution, and in vivo performance
P2860
Q21558465-79E37582-5ADA-43B0-BCFE-5CF56A48652CQ33499119-5614FFBD-C04D-4BDA-8424-82AD31B84340Q33807145-7CAF3D56-7CE2-4FD2-BADE-CA04FAA4AE3FQ34058540-0695203B-2EFD-49CB-B626-DE4DCBB2E845Q34127212-8CE3CEE2-3E7F-453C-9C8B-E8802B6EBE81Q34286341-DA3C18E9-5631-4B05-9A32-DF5E5061AFA8Q34431310-4CA95DAB-93F2-4FF1-AC1A-3C0D60DEE2C7Q35138738-32563D2A-1B2E-443A-8E34-890062273F36Q35401667-6C13CCF5-DAC1-4D6B-9A52-9181DD944F8DQ35401716-CEF14606-190E-482D-935E-B66C8D826AD0Q35764409-DE74E449-175E-436E-96D2-C466FBBFFB7BQ36493977-94F45AF9-CCB3-4CA4-BBC0-9B26F7742950Q36532110-D251F195-B9F6-48F1-8280-66CA030C2B67Q36563827-EE51A119-EEE6-4DDE-BBB5-F374F932ED62Q36664997-79288E94-8AB1-4256-A00E-0E264CF6BA49Q36908847-FD1B67CB-1CC0-4B4D-AB5F-5BC718A30C7CQ36945535-B7EBD1BC-638E-4AEA-B509-1AB2926253F2Q37013406-342A4030-9A54-4933-A0F0-9024B8650028Q37042365-BCF835A1-B35B-4C05-9B87-743A2D7EA0CFQ37095819-975AFDB1-3AC6-472B-995A-EC6C1FCCBAA7Q38722530-908C14AA-79A6-49FD-9B55-C5F9C4829CC5Q39298900-67FBC523-994B-4E6F-B2BC-2650C1E95630Q39661482-EC2DB188-287C-4B98-85B9-15A1000A7ECBQ39717889-39240ABC-A773-413A-BF5A-43E3507664FAQ40688083-30694582-1729-4969-9DA9-01755DA4BCB5Q42120578-66F1A5EB-1DB1-4141-85EF-47720CC70F79Q42147079-2ACFFC96-0021-4DE8-BF98-B454A8B7D49EQ42511450-EA27C625-73AB-4707-889A-ED02E7AC4996Q42776481-3E8E36ED-BE45-4AE7-BA39-EDC8C22ED9B4Q45056589-BE3DE548-02BB-4037-89BB-05ADAA2AE95DQ46547178-A5C63D7A-9B4A-4009-A650-886CDAACEE26Q46850551-34DAE152-4F5F-493E-8CE0-D9FA158B0DD2Q48221452-88E29FF2-E42F-4C73-83EF-D46614300EB0Q49244460-C4547AD6-81DD-436E-86D8-A5F05E0FEFB9Q50044384-C03662BE-192D-4393-A385-2D341F865543Q51807216-1F5692C9-F435-46E1-BA0F-F628D9E4555EQ52724728-EFF21859-998D-4550-81E2-9D1159209688Q57138111-744958AC-B9AB-4B32-9FEB-ACB45E99127EQ59125766-826E6689-4ECC-4961-B802-2756EDC41296
P2860
Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@ast
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@en
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@nl
type
label
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@ast
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@en
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@nl
prefLabel
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@ast
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@en
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@nl
P2093
P356
P1433
P1476
Antitumoral actions of the ant ...... of Her2/neu (erbB-2) oncogene.
@en
P2093
P304
P356
10.1093/ANNONC/MDI239
P577
2005-05-03T00:00:00Z